Trade Spyre Therapeutics Inc. - SYRE CFD

Aeglea Bio Therapeutics Company profile

About Aeglea Bio Therapeutics Inc

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aeglea Bio Therapeutics Inc revenues increased from $0K to $18.7M. Net loss decreased 19% to $65.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.33.

221 Crescent Street
Suite 105
WALTHAM
MASSACHUSETTS 02453
US